Company: OCEA
Filing Date: 2025-04-08
Form Type: 10-K
Source: 0001641172-25-003155
Chunk: 2264

Company: Ocean Biomedical, Inc.
Filing Date: 2025-04-08
Form: 10-K
Item: Item 1A
Chunk 2264
---
 at or above price you
paid for them.

There
is a limited public market for our common stock and warrants. You may not be able to sell your shares or warrants quickly or at the market
price if trading in our common stock or warrants is not active. An active or liquid market in common stock and warrants may not develop
or, if it does develop, it may not be sustainable. As a result of these and other factors, you may be unable to resell your shares of
our common stock or warrants at or above price you paid for them.

Further,
an inactive market may also impair our ability to raise capital by selling shares of our common stock and may impair our ability to enter
into strategic collaborations or acquire companies or products by using our shares of common stock as consideration.

The
price of our common stock and warrants may be volatile, and you could lose all or part of your investment.

The
trading price of our common stock and warrants may be highly volatile and could be subject to wide fluctuations in response to various
factors, some of which are beyond our control, including limited trading volume. In addition to the factors discussed in this “Risk
Factors” section and elsewhere in this Annual Report on Form 10-K, these factors include:

    ●
    the
    commencement, enrollment or results of any clinical trials of any of our programs;

    ●
    any
    delay in identifying and advancing a clinical candidate for our other development programs;

    ●
    any
    delay in our regulatory filings of our product candidates and any adverse development or perceived adverse development with respect
    to the applicable regulatory authority’s review of such filings, including without limitation the FDA’s issuance of a
    “refusal to file” letter or a request for additional information;

122

    ●
    adverse
    results or delays in our clinical trials;

    ●
    our
    decision to initiate a clinical trial, not to initiate a clinical trial or to terminate an existing clinical trial;

    ●
    adverse
    regulatory decisions, including failure to receive regulatory approval of any product candidate;

    ●
    changes
    in laws or regulations applicable to any product candidate, including but not limited to clinical trial requirements for approvals;

    ●
    adverse
    developments concerning our manufacturers;

    ●
    our
    inability to obtain adequate product supply for any approved product or inability to do so at acceptable prices;

    ●
    our
    inability to establish collaborations, if needed;